HIM
ORMP icon

Hillsdale Investment Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Hillsdale Investment Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$331K Buy
+97,300
New +$330K 0.01% 483

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Hillsdale Investment Management's ORMP Position: Q1 2026 in Review

Hillsdale Investment Management opened a new position in Oramed Pharmaceuticals (ORMP) in Q1 2026: 97,300 shares worth $331K. The stake represents 0.01% of the portfolio and ranks #483 among its holdings.

64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Hillsdale Investment Management held 97,300 shares of Oramed Pharmaceuticals worth $331K as of Q1 2026.
  • Oramed Pharmaceuticals was a new Hillsdale Investment Management position in Q1 2026.
  • Oramed Pharmaceuticals made up 0.01% of Hillsdale Investment Management's portfolio in Q1 2026, its #483 holding.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.